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CHARACTERIZING HETEROTOPIC OSSIFICATION DEVELOPMENT 
FOLLOWING MUSCLE INJURY 




Musculoskeletal trauma is a well-known cause of heterotopic ossification, also 
known as ectopic ossification, a pathological process in which bone forms within 
soft tissues. Previous studies in the lab have shown that muscle trauma 
increases the amount of bone formed in demineralized bone matrix-induced 
animal models. Moreover, recent studies have shown that ectopic ossification's 
underlying mechanism follows a specific gene expression progression similar to 
endochondral ossification. Because of the inherent complexity of the biological 
composition of DBM, the need to use immune deficient animals with human 
DBM, and the experimental objective to clarify the role of BMP2 in the inductive 
process on musculoskeletal trauma on ectopic bone formation a simpler and 
better defined model of inducing ectopic bone formation was examined. For the 
studies reported here, defined concentrations of BMP2 were added to gelatin 
sponges in combination with a defined muscle injury to induce ectopic bone 
formation on bone formation.  
Objective: 
Characterize the effects muscle trauma on ectopic bone formation using 
absorbable gelatin sponge/BMP2 – induction model for ectopic bone formation. 
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Bone volume and structure were assessed by MicroCT. The quantitative 
expression of specific mRNAs  was used to examine: the induction and 
recruitment of stem cells: skeletal cell development and differentiation; and BMP 
signaling.  
Methods: 
Tamoxifen inducible B6.Cg-Pax7tm1(cre/ER2)Gaka/J transgenic mice were crossed 
with B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J to create Pax7/Ai14 reporter. 
These animals were subsequently crossed with B6.129S7-Rag1tm1Mom/J mice. 
This created an inducible reporter mouse capable of receiving the absorbable 
gelatin sponge loaded with recombinant human bone morphogenic protein 2 
(BMP-2). Between 8-10 weeks of age, mice received two tamoxifen injections 
within 48 hours apart, followed by a washout period of 96 hours. Animals were 
implanted with 0.2 cm3 of sterile absorbable gelatin sponged loaded with 0.3 µg 
of BMP-2 along the periosteal surface of the femur bilaterally. Muscle injury was 
induced in select animals following surgery. Animals were harvested at either 
postoperative day (POD) two, eight, or sixteen. Tissue samples were either 
prepared for plain film radiographs and micro-computed tomography (µCT) or 
mRNA extraction. Samples selected for imaging were radiographed using plain 
film and then proceeded for µCT. Micro-computed tomography allowed for 
analysis of the ectopic bone and the creation of 3D renderings. Implant samples 
selected for mRNA extraction were further prepared to analyze gene expression 




Muscle trauma did not significantly change the characteristics of ectopic bone 
formed in the BMP-2 supplemented absorbable gelatin sponge implant. 
However, a batch effect had been observed between samples that received two 
different batches of BMP-2, which differed significantly in tissue volume and 
trabecular morphology. Gene expression showed a progressive pattern of 
expression. Sox2 expression peaked early in POD 2 samples. In comparison, 
Prx1 and α-SMA expression peaked later on at POD 8 and 16. Early markers of 
chondrogenesis, Sox9, and Acan, peaked at POD 8, while late makers of 
chondrogenesis, Col10a1, and osteogenesis markers, RUNX2, Sp7, and DMP-1, 
peaked at POD16. Expression of various members of the BMP gene family 
showed that BMPs were endogenously induced over the course of ectopic bone 
formation and suggests that BMP signaling is central to progressive development 
of ectopic bone formation.   
Conclusion: 
Skeletal muscle injury does not appear to significantly impact the formation of 
ectopic bone in gelatin sponge implants supplemented with 0.3 µg of BMP-2. 
However, batch 2 samples showed some distinction between injured and 
noninjured samples, but the sample size was too small to make any firm 
conclusion. Further studies with the same protocol would help create a more 
definitive conclusion. RNA analysis reaffirmed a previous study's findings 
showing a progression of gene expression similar to endochondral ossification. 
 
 viii 
However, this study produced evidence suggesting a delay in either 
osteogenesis or in the apoptosis and resorption of the hypertrophic cartilage 
within this model. Further studies could introduce later harvest times at 21 or 31 
days postoperative, allowing a better understanding of when osteogenesis peaks 
during ectopic ossification.   
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 Fractures are one of the most frequently seen large-organ injury 
with around 16 million fractures annually in the United States alone. These 
fractures will heal to their pre-injury state most of the time; however, 
approximately 5-10% will result in impaired healing or nonunion (Coates et al., 
2019; Einhorn & Gerstenfeld, 2015). Complications like these lead to increased 
hardship to the patient, including potential disability, decreased quality of life, the 
increased financial burden with prolonged healthcare management, and 
prolonged prescription usage (Ekegren et al., 2018). Current treatment options 
can be categorized as either physical stimulation, which utilizes devices to 
mechanically stimulate bone formation by applying stress onto the bone tissue, 
or biological therapies, including autologous growth factors or hormones to 
promote osteogenic cell differentiation and proliferation. The current gold-
standard treatment to enhance bone regeneration is autologous bone grafting, 
often using the iliac crest due to enrichment of both osteogenic and angiogenetic 
progenitor cells. Despite the excellent results with this procedure, it is costly and 
frequently associated with pain and other complications such as injury, 
hematoma, and even fracture at the harvest site (Buza & Einhorn, 2016). These 
limitations emphasize the need to further understand the biological processes 
involved in bone formation and fracture healing to find novel treatments that are 
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 Bone ossification or osteogenesis is divided into two distinct types, 
intramembranous and endochondral. Intramembranous ossification utilizes a 
template of condensed mesenchymal cells that directly differentiate into 
osteoblasts, which secrete an unmineralized collagen-proteoglycan matrix that 
later binds calcium hardening and forming bone. This is the predominant process 
during clavicle development and most of the craniofacial skeleton (Breeland et 
al., 2020). In contrast, the remainder of the axial skeleton and appendicular 
skeleton develops through endochondral ossification, which, as shown in Figure 
1, uses hyaline cartilage as an intermediate tissue that is gradually replaced with 
bone (Vortkamp et al., 1998). The progression of bone development through 
endochondral ossification can be summarized into five stages: the condensation 
of mesenchymal cells at the site of a future bone, development of a hyaline 
cartilage model, calcification of cartilage and formation of the bone collar, the 
formation of the primary ossification center, and the formation of secondary 
ossification centers (Breeland et al., 2020). 
           The process of skeletogenesis begins with the migration of mesenchymal 
stem cells from their embryonic origin to the site of the future bone, where the 
cells condense into the shape and size that will serve as a model of the future 
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bone (Berendsen & Olsen, 2015). This mesenchymal condensation is 
characterized by a densely packed cluster of cells with increased expression of 
neural cell adhesion molecules and neural cadherins, which mediate cell-cell 
adhesions during this phase. Several molecules have been shown to contribute 
to the aggregation of mesenchymal cells, including Homeobox A 13, Homeobox 
D 13, bone morphogenetic proteins (BMPs), noggin (NOG), and fibroblast growth 
factors (FGFs) (Long & Ornitz, 2013). 
           Transition to the next phase of endochondral ossification is marked by the 
acquisition of chondrogenic potency by the mesenchymal cells and differentiation 
into chondrocytes. This commitment to the chondrocyte lineage is regulated by 
the expression of sex determining region Y (SRY)-box 9 (Sox9). Sox9 further 
activates two other member Sox family transcription factors, SRY-box 5 (Sox5) 
and SRY-box6 (Sox6), which cooperate with Sox9 in chondryocytic differentiation 
(Akiyama & Lefebvre, 2011; Bi et al., 1999). The Sox5, Sox6, and Sox9 form a 
Figure 1: Overview of Endochondral Ossification. Illustrative depiction of endochondral 
ossification progression through several stages. Modified from (Allas et al., 2019). 
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trio of transcription factors that are essential for the expression of several 
chondrocyte-specific genes including, collagen type 2 alpha 1 (Col2a1) and 
aggrecan (Acan), genes that encode for the dominant fibrous and ground 
substance components of hyaline cartilage (de Crombrugghe et al., 2000; Han & 
Lefebvre, 2008). Simultaneously, Sox5, Sox6, and Sox9 stimulate the rapid 
proliferation of chondrocytes leading to linear growth (Allas et al., 2019). In 
addition to stimulating proliferation, previous research has identified Sox9 
expression in chondrocytes as a vital regulator of endochondral ossification 
progression through hypertrophy inhibition (Akiyama et al., 2002; Bi et al., 2001). 
Conversely, the expression of Runt-related transcription factor 2 (RUNX2) 
initiates as chondrocytes begin to hypertrophy and is maintained throughout the 
hypertrophic cell's life. Expression of RUNX2 facilitates the transcription of 
collagen type 10 alpha 1 (Col10a1), metallopeptidase 13, and vascular 
endothelial growth factor (VEGF), factors that facilitate the remodeling of the 
cartilage matrix and infiltration of blood vessels essential for osteogenesis (Hata 
et al., 2017; Hattori et al., 2010). 
 The expression of RUNX2 primarily regulates the commitment to the 
osteogenic lineage and is upstream of osterix (Sp7). Previous studies 
demonstrated mutant mice lacking either RUNX2 or Sp7 failed to produce 
osteoblasts (Komori et al., 1997; Nakashima et al., 2002). In turn, RUNX2 and 
Sp7 regulate the expression of alkaline phosphatase, secreted phosphoprotein 1, 
and bone gla protein, essential osteoblast-specific genes (Ohba, 2020). Several 
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extracellular factors have been shown to regulate the expression of RUNX2 and 
Sp7, including Indian hedgehog (IHH), NOG, Wnts, BMPs, and FGFs, and by 
doing so, regulating the differentiation of osteoblasts (Long & Ornitz, 2013). Of 
these, BMPs are one of the best-understood regulators of osteogenesis. It is 
currently understood that the binding of BMPs to both bone morphogenetic 
protein receptor type 1 (BMPR-1) and type 2 (BMPR-2) permits the 
phosphorylation of BMPR-1 by BMPR-2, which is constitutively active, activating 
the type 1 receptor kinases. In turn, BMPR-1 kinases phosphorylate Smad1, 
Smad5, or Smad8, which will form a complex with Smad4 and bind to DNA, 
upregulating the expression of osteogenic genes like RUNX2 and Sp7 as well as 
upregulating inhibitor of DNA binding 1 (Id-1), which inhibits myogenesis (B. 
Bragdon et al., 2011; Katagiri et al., 2015).   
Early sources of osteogenic precursors contributing to endochondral 
ossification are the diaphyseal perichondrium adjacent to pre-hypertrophic and 
hypertrophic chondrocytes. As opposed to intramembranous ossification, the 
secretion of IHH by these hypertrophic cells is vital in inducing RUNX2 and Sp7 
expression in perichondrial osteogenic progenitor cells during endochondral 
ossification and leading to the formation of the bone collar (St-Jacques et al., 
1999). Following the bone collar development, osteogenic progenitor cells 
infiltrate the diaphysis via blood vessels formed due to VEGF expression by 
hypertrophic chondrocytes. These osteogenic progenitor cells differentiate into 
osteoblasts and form the primary ossification center. These steps will then be 
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repeated at each epiphysis and form the secondary ossification centers (Hallett 
et al., 2019).  
 
Heterotopic Ossification 
Heterotopic ossification (HO), also referred to as ectopic ossification, is 
the abnormal deposition of bone within soft tissue, like skeletal muscle, tendons, 
ligaments, and nervous tissue (Barfield et al., 2017). HO is divided into two 
forms, trauma-induced and the much rarer genetic form. One of the most 
debilitating genetic HO is fibrodysplasia ossifcans progressiva (FOP). FOP is 
characterized by episodic inflammation of the soft tissues, which results in the 
formation of bone replacing skeletal muscle and connective tissues leading to the 
progressive immobility of joints (Kaplan et al., 2013). Causes of FOP have been 
linked to a dysregulation of the BMP pathway, and in particular, one study 
identified the activin A type 1 receptor (ACVR1), a BMPR-1, gene as a common 
mutation in both familial and sporadic cases of FOP (Shore et al., 2006). This 
mutation results in the destabilization of the receptor's glycine-serine activation 
domain, leading to a loss of its autoinhibition, leading to the expression of 
downstream osteogenic genes (Kaplan et al., 2013).  
Acquired HO can occur following several types of tissue trauma, including 
fractures, orthopedic surgeries, burns, amputations, and blast injuries. The 
incidence of HO in the population has a high degree of variability depending on 
the trauma. Fractures and dislocation have shown to have an incidence of 30%, 
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while spinal cord injuries and severe amputations have shown occurrences 
upwards of 50% and 90%, respectively (Meyers et al., 2019). The mechanisms 
that drive acquired HO are not yet fully understood. The BMP signaling pathway 
is a critical participant in upregulating osteogenic gene expressions like RUNX2 
and Sp7. However, several other pathways may play a role in regulating 
osteoblast differentiation via an independent mechanism or BMP crosstalk; these 
include the transforming growth factor beta, pathogen-associated molecular 
patterns, and damage-associated molecular patterns, Wnt/beta-catenin, 
hedgehog (HH), and mechanistic target of rapamycin kinase pathways (C. Kan et 
al., 2018; Pulik et al., 2020). 
One of the biggest concerns currently with HO is the lack of viable non-
operative management. Current methods focus on preventative care using non-
steroid anti-inflammatory drugs (NSAIDs), radiotherapy, and bisphosphates. The 
effectiveness of bisphosphates has been put into question, and though NSAIDs 
and radiotherapy have shown to decrease HO incidence, there are significant 
risks, particularly as prophylaxis following fracture surgery. However, once an 
individual develops HO, minimal that can be done non-operatively, and 
symptomatic patients likely proceed to excisional surgery (Eisenstein et al., 
2018). 
Current studies into HO have utilized animal models to study the 
underlying mechanisms and discover more efficient and effective treatments of 
this pathological process. Animal models are typically divided into those 
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designed to mimic the hereditary form of HO and those that replicate the 
acquired form. The most common genetic models use animals with mutations to 
the ACVR1 resulting in constitutive activation and upregulation of downstream 
osteogenic genes, leading to ectopic ossification through an FOP-like 
mechanism. Conversely, several acquired HO models are currently used, of 
which BMP injection/implantation is one of the most commonly used due to its 
simplicity and reproducibility (Cappato et al., 2020; L. Kan & Kessler, 2011). 
Though these models provide a good representation of heterotopic ossification, 
its application clinically is limited by its failure in addressing one of the most 
common causes of HO in humans, trauma. Liu et al. developed a model to 
address this issue by injecting mice quadriceps with hydrogel and bone 
morphogenetic protein 2 (BMP-2) and inducing trauma. Their study found that 1 
µg of BMP-2 combined with muscle trauma significantly increased bone 
mineralization compared to animals that only received 1µg BMP-2 injections. 
This model provided a better representation of post-traumatic HO and a new 
model to study the pathological process mechanisms (Liu et al., 2014). 
 
Stem Cells 
 Stems cells are a type of cell that maintains self-renew capability and 
potency to differentiate into a more specialized cell. The potency of a stem cell 
refers to its ability to differentiate into different cell lineages. Stem cells are 
classified by their potency and are as follows: totipotent, pluripotent, multipotent, 
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and unipotent. A stem cell that can differentiate into every cell type, including that 
of the placenta and other extraembryonic tissues, is termed a totipotent stem cell. 
On the other hand, pluripotent stem cells can differentiate into every cell type 
originating from the three primary germ layers. Once a stem cell can only 
differentiate into a cell line of a specific germ layer, it is referred to as a 
multipotent stem cell (B. C. Bragdon & Bahney, 2018). Several stem cells 
continue to exist in the adult body referred to as adult stem cells or somatic stem 
cells. These cells function to regenerate specific tissues postnatally and exist in 
niches throughout the body, including the blood, intestine, skin, hair follicle, and 
bone (Matsushita et al., 2020).  
 The process of fracture healing and heterotopic ossification rely on 
multipotent stem cells' presence and ability to differentiate into osteoblasts. The 
periosteum, endosteum, and bone marrow have been known to contain 
osteogenic progenitor cells contributing to fracture healing. However, recently it 
has been speculated that satellite cells from skeletal muscle and pericytes from 
vessel walls contribute to the overall process (B. C. Bragdon & Bahney, 2018). 
 
Skeletal Muscle & Satellite Cells 
 Skeletal muscle is one of the three types of muscle found in the body. It 
performs various functions, from the more commonly known locomotion and 
posture maintenance to the secondary roles in metabolic regulation of amino 
acids and glucose (Frontera & Ochala, 2015). Structurally, skeletal muscle is a 
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highly organized tissue composed of myofibers at its basic cellular level. Each 
myofiber is composed of many myofibrils, which run the entire length of the 
myofiber. Myofibers themselves arrange as a bundle of fibers forming a fascicle, 
which further organize with other fascicles to form the complete muscle tissue 
(Mukund & Subramaniam, 2020). 
 Like bone, skeletal muscle has a degree of regenerative capability, 
dependent on the niche of adult stem cells located between the sarcolemma and 
basal lamina of muscle fibers called satellite cells. These cells, characterized by 
their expression of paired box 7 (Pax7), are predominantly quiescent and remain 
within their niche until activation following an injury to the surrounding muscle 
tissue (Chen & Shan, 2019). Muscle regeneration is divided into three phases: 1) 
the inflammatory phase, 2) the satellite cell activation and differentiation phase, 
and 3) the maturation and remodeling phase.  
Upon muscle injury, muscle tissue begins to degenerate, leading to 
necrosis of the tissue. This pathological change induces an inflammatory 
response and the recruitment of circulating leukocytes, including neutrophils and 
two different populations of macrophages, differentiated by their surface markers 
cluster of differentiation (CD)68+/CD163- and CD68-/CD163+. The CD68+/CD163- 
macrophages secrete pro-inflammatory cytokines interleukin -1 and tumor 
necrosis factor-alpha, while the CD68-/CD163+ population of macrophages 
secretes anti-inflammatory cytokine, interleukin-10, which has shown to induce 
 
11 
satellite cell proliferation and differentiation (Arnold et al., 2007; Schmidt et al., 
2019; Yin et al., 2013). 
Activation of satellite cells is regulated by several factors, including Wnt, 
Notch, and sphingolipid signaling. Interestingly, the population of satellite cells 
involved in regeneration is not localized to the site of injury. Rather satellite cells 
along the entire myofiber as well as from adjacent fibers and muscles migrate to 
the site of injury. Once activated, satellite cells will begin to express either 
myogenic factor 5 or myoblast determination protein 1 (MyoD), which controls the 
process the cell progresses down; Myogenic factor 5 leads to enhanced 
proliferation MyoD leading to myogenic differentiation.  Increased levels of MyoD 
in the cell will upregulate downstream myogenic targets, myogenin, myogenic 
factor 6, and myocyte enhancer factor-2 leading to differentiation into myoblasts. 
These myogenic cells will fuse with the damaged myofiber, leading to the 
formation of a nascent muscle fiber indistinguishable from uninjured fibers (Yin et 
al., 2013).  
 
Role of Muscle In Osteogenesis 
 It has long been understood that surrounding muscle has a pro-osteogenic 
effect on fracture healing, with studies having shown that covering fractures with 
a flap of muscle tissue has increased bone density and union strength (Harry et 
al., 2008; Richards et al., 1991). The role that muscle tissue plays during fracture 
healing is multi-modal, with evidence suggesting it plays a role in providing a 
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vascular supply to bone ends, a source of osteoprogenitor cells, a source of 
cytokine and other extracellular factors, and lastly, an anti-microbial environment 
(Chan et al., 2012). More recently, muscle injury has shown to stimulate ectopic 
osteogenesis within HO animal models injected with BMP-2 via increased 
production of bone morphogenetic protein 7 (BMP-7), creating an osteoinductive 
microenvironment, further supporting the idea that muscle injury plays a role in 
the formation of bone. Several progenitor cell populations have been identified 
within muscle tissue that has osteoblastic potential. Of these, satellite cells have 
been shown to differentiate into the chondrocyte lineage and contribute to the 
fracture callus endogenously though the contribution was minimal compared to 
contribution following transplantation (Abou‐Khalil et al., 2015). Interestingly, later 
studies indicated that satellite cells rarely differentiate into osteoblasts (Matthews 
et al., 2016). 
 However, previous studies performed in the lab used Pax7/Ai14/Rag 
inducible reporter mice to lineage trace Pax7-positive cells following muscle 
injury in a BMP-2 implantation mouse model using DBM. These experiments 
showed the appearance of Pax7-positive cells within ectopic bone formed 
following muscle injury, suggesting that muscle trauma stimulates the recruitment 
of satellite cells and contributes to osteogenesis (W. T. Moore, 2019). Despite 
this, the underlying signaling pathways and the genes involved are not yet fully 
understood. Therefore, this study aims to clarify the various genes involved in 





Aim 1: Compare the development of ectopic bone with and without muscle injury. 
Use X-ray imaging, micro-computed tomography, and quantitative real-time 
polymerase chain reaction to evaluate ectopic bone development differences 
over time. 
 
Aim 2: Determine the impact muscle trauma to surrounding skeletal muscle has 
on ectopic bone formation in mice with periosteal BMP-2 loaded gelatin sponges. 
Use of micro-computed tomography to quantify the volume of periosteal bone 







Unless stated otherwise, materials and equipment used were supplied by 
Thermo Fischer Scientific (Waltham, MA). 
 
Animals 
 All animal studies were approved by the Institutional Animal Care and Use 
Committee at Boston University. Mice used in studies were housed under 
standard conditions at the Boston University Animal Facilities. Mouse strain 
Pax7cre/Ai14/Ragtm1 was bred in-house for use in these studies as previously 
described (W. T. Moore, 2019). Both female and male mice were used. All mice 
used were 8-10 weeks of age at the time of surgery. Before beginning any 
experimentation, mice were evenly assigned to either receive muscle trauma or 
not immediately following surgery and were further distributed for harvesting at 
postoperative days 2 (n = 10), 8 (n = 11), and 16 (n = 24).  
 
Tamoxifen Injections 
 Tamoxifen solution was prepared at a 10 mg/mL concentration by adding 
400 mg of tamoxifen powder (Sigma-Aldrich®, St. Louis, MO) to 40 mL of corn 
oil. Complete solvation of the tamoxifen was achieved through multiple rounds of 
sonicated ice-cold ethanol baths until the tamoxifen powder was no longer 
visible. The dissolved tamoxifen solution was then filtered sterilely using a 10-mL 
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syringe and an in-line 0.45 μm sterile filter. The solution was then aliquoted into 2 
mL tubes and stored at -80 °C. 
 Mice received two tamoxifen injections intraperitoneally, 48 hours apart, at 
a dose of 10 μL/g of body weight. Surgery was then performed after a washout 
period of 96 hours.  
 
Sponge Implant Surgery 
 Mice were anesthetized using a 4% isoflurane in 100% oxygen mix in an 
anesthesia chamber. Once animals were anesthetized, the mice were transferred 
to a heated operating field, and a nose cone delivering 2% isoflurane was used 
to maintain anesthesia. Prior to incision, mice received subcutaneous injections 
of 0.01 mL of 2.27% Baytril, an antibiotic, and 0.1 mL of Buprenex, an analgesic. 
Surgical sites were shaved using electric clippers and prepped with Betadine. An 
incision was created at the lateral hindleg of each limb, providing access to the 
femur. Before implantation, a Surgifoam® absorbable gelatin sponge was loaded 
with 0.3 μg of BMP-2. The loaded sponge was implanted in each hind limb 
against the femoral periosteum. Following implantation and closure of the 
incision, muscle trauma was induced to assigned animals by dropping a blunt 
mass from a height of 31 mm (Grode et al., 2017). 
 
Harvest & X-ray Imaging 
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 Mice were harvested at either postoperative days (POD) 2, 8, or 16. 
Euthanasia was carbon dioxide inhalation followed by cervical dislocation. Limbs 
intended for mRNA extraction had the femur, implant, and muscle separated and 
individually placed into a sterile 2 mL microcentrifuge tube and snap-frozen in 
liquid nitrogen and stored at -80 °C until extraction.  
Samples used for x-ray imaging and micro-computed tomography were 
collected and fixed in 4% paraformaldehyde (Sigma-Aldrich®, St. Louis, MO) at 4 
°C for 72 to 96 hours and then washed three times with 1X phosphate buffer 
solution (PBS). X-ray imaging was performed using the Faxitron MX-20 
Specimen Radiography System (Tuscon, AZ), at a setting of 30 kV for 40 
seconds, with Denville Scientific HyBlot CL film (Metuchen, NJ) and then stored 
in 1X PBS at 4 °C until needed for analysis. Films were developed using a 
Konica Minolta SRX-101A film processor (Wayne, NJ). 
 
Micro-Computed Tomography  
 Micro-computed tomography (µCT) was performed only on POD 16 
samples, as previous studies in this lab found the earliest time point for 
mineralization was postoperative day 12, which was consistent with x-ray 
imaging of POD 8 samples (B. Bragdon et al., 2017). Micro-computed 
tomography was performed using the SCANCO Medical μCT 40 Scanner 
(SCANCO USA Inc., Wayne, PA). Samples were placed in a 20.5 mm tube and 
scanned at 70 kVp, 114 μA, a medium resolution, and an integration time of 200 
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ms. Images were manually contoured around the ectopic bone, and analysis of 
the ectopic bone volume (BV) was calculated using the SCANCO Medical 
program at a threshold of 222 as was measured in a previous study performed in 
the lab (W. T. Moore, 2019). Three-dimensional (3D) renderings were created 
using the Microsoft ® Paint 3D. 
 
RNA extraction 
 Chemical extraction was used to isolate mRNA from the implant. Tissue 
samples were placed in 2 mL Eppendorf tubes with 750 mL of QIAzol® Lysis 
Reagent (Qiagen® 79306). Samples emersed in the lysing reagent were frozen 
for at least 10 seconds in liquid nitrogen. A 5 mm stainless steel bead (Qiagen®) 
was added to each tube before being placed in cassettes (Qiagen®) and lysed 
using the Qiagen® Tissue Lyser II at 30 Hz. Samples were checked every 2 
minutes, and care was taken to refreeze thawed samples if tissue was not 
completely lysed. Once lysis was complete, samples were moved to another 2 
mL tube containing 1 mL of QIAzol® Reagent (Qiagen® 79306) and placed on 
ice for at least two minutes. 
 Samples were then treated with 200 µL of chloroform (Sigma-Aldrich®), 
vortexed, and set on ice for another 2 minutes. These samples were vortexed 
again before being centrifuged for 15 minutes at 1400 rpm and 4°C. The 
aqueous phase of each tube was carefully transferred to a new tube, and an 
equal amount of isopropanol was added. Tubes were then inverted several 
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before centrifuging for 30 minutes at 1400 rpm and m and 4 °C. After 30 minutes, 
the supernatant was poured out carefully to avoid losing the pellet containing the 
RNA. The pellet was then washed twice, with 500 mL of 70% ethanol (Sigma-
Aldrich®), and then centrifuged for 5 minutes at 1400 rpm and 4 °C. Following 
the final wash, the tube was inverted and placed on a Kimwipe to dry. After 
drying, the pellet was resuspended in RNAse-free water. Femur and muscle 
samples were resuspended in 50 µL of RNAse-free water, while implants were 
resuspended in 30 µL. Extracted mRNA samples were stored at -80 °C. 
 
Gel Electrophoresis and Spectroscopy 
The quality and concentration of the extracted RNA were analyzed using 
gel electrophoresis and spectrophotometry. Gel electrophoresis was performed 
using a 1.5% agarose gel, made with UltraPure™ agarose from Invitrogen and 
GelStar™ Nucleic Acid Gel Stain from Lonza Group. Loading samples were 
prepared by combing 7 µL of water, 2 µL of 6XAgarose Gel Loading Dye, and 1 
µL of the extracted RNA. The gel was run at 100 V for approximately 90 minutes. 
Gels were then placed under ultraviolet light to observe bands indicating the 
presence of nucleic acids.  
Spectophotometry was used to quantify the concentration and the purity of 
the RNA. A tray containing 16 cuvettes was loaded with 2 µL of RNA sample with 
at least two cuvettes filled with RNAse-free water as a control. The loaded tray 
was placed in the NanoDrop-1000 Spectrophotometer, and sample 
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concentrations (ng/µL) and purity ratios (260 nm/280 nm) were measured. 
Sample concentrations above 100 ng/µL were large enough for complementary 
DNA (cDNA) production. Samples above 2000 ng/µL required further dilution with 
RNAse-free water, and spectrophotometry was repeated. Purity ratios above 1.7 
were deemed acceptable for cDNA production. RNA samples with ratios below 
1.7 were purified. 
 
RNA Purification 
 Samples were prepared for purification by combining 15 µL of the 
extracted RNA sample with 1.5 µL of 5M sodium chloride solution and 20.7 µL of 
100% ethanol. Each sample was then pipetted onto a filter cartridge placed 
inside a collection tube. The collection tube containing the filter cartridge was 
then centrifuged for 15 seconds at 10,000 rpm. The flow-through in the collection 
tube was discarded, and 700 µL of miRNA Wash Solution 1 was pipetted onto 
the filter cartridge and centrifuged for 10 seconds at 10,000 rpm. Flow-through 
was discarded, and 500 µL of Wash Solution 2/3 was added to the filter cartridge 
and centrifuged for 10 seconds at 10,000 rpm. Flow-through was discarded, and 
a final wash was performed using another 500 µL of Wash Solution 2/3 and 
centrifuged for another 10 seconds at 10,000 rpm. Flow-through was discarded, 
and the collection tube containing the sample was centrifuged for 1 minute to 
remove any residual fluid from the filter. The filter cartridge was then removed 
and placed into a new collection tube, and 50 µL of RNase-free water was added 
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to the filter cartilage and centrifuged for 30 seconds at 14,000 rpm. The elute 
from this final spin contained the purified RNA. The quality and purity of the 
purified RNA was again tested before being stored at -80 °C. 
 
cDNA Production 
 A volume containing 1 µg of RNA from each sample was added into a 0.2 
mL PCR tube. RNAse-free water was added at varying amounts to bring the final 
total of each tube to 10.4 µL. Reagents and enzymes from the Tawman Reverse 
Transcriptase Kit were added into a 2 mL Eppendorf tube to create a master mix 
containing the following volume of reagents per sample, 6.61 µL of MgCl2, 6.0 µL 
of dNTP Mix, 3.0 µL of 10X RT Buffer, 1.5 µL if Random Hexamers. After 
combining the reagents, the mixture was vortexed to homogenize the solution. 
After vortexing, the enzymes RNAse Inhibitor and Taqman Reverse 
Transcriptase were added to the master mix at a ratio of 0.6 µL and 1.89 µL per 
sample, respectively, and mixed by pulsating or gently flicking the tube. From the 
master mix, 19.6 µL was added to each of the previous PCR tubes containing the 
RNA sample. 
 Samples were then loaded into an Eppendorf Mastercycler® Personal 
thermal cycler and underwent a polymerase chain reaction at the following 
settings: 25 °C for 10 minutes, 37 °C for 60 minutes, 95 °C for 5 minutes, and 
finally, a 4 °C hold. The resulting cDNA was then diluted with RNAse-free water 




Quantitative Polymerase Chain Reaction 
 Quantitative polymerase chain reaction (qPCR) was performed using the 
diluted cDNA for each sample. A master mix was created containing TaqMan® 
Universal PCR Master Mix from Applied Biosystems® and TaqMan® Gene 
Expression Assay from Applied Biosystems® at a ratio of 10 µL and 1 µL per 
sample, respectively. A list of primers used in this study can be found in Table 1. 
A 96-well qPCR plate was then filled with 11 µL of the master mix and 9µL of the 
diluted cDNA. Each sample was run in doublet. As a control, 9 µL of RNAse-free 
water and 11 µL of the master mix was also run as a doublet. 
Additionally, bone and muscle samples from non-operated 
Pax7cre/Ai14/Ragtm1 were used to normalize the cycle threshold (Ct) values. 
The plate was then covered with a Microamp™ optical adhesion film and then 
centrifuged to remove any air bubbles at 1500 rpm for 2 minutes. Analysis of the 
plate was done using the AVI 7700 Sequence Detector® from Applied 
Biosystems®. The qPCR proceeded in the following steps: 50 °C for 2 minutes, 
95 °C for 10 minutes, 40 cycles at 95 °C, each lasting 15 seconds, and 60 °C.  
 
Statistical Analysis 
 Statistical analysis was performed using JMP® Pro 15.2.0. Analyses 
included multiple Student t-tests when comparing two groups, and one and two-
way analysis of variance (ANOVA) followed by the Tukey multiple comparison 
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tests were performed when comparing three or more groups, with significance 
being p < 0.05. Charts and graphs were created using Microsoft® 365 Excel. 
  
Primer Catalog Number 
Table 1: qPCR Primers. 
Primers and corresponding 
catalog numbers. 
Normalization Primer  
18s Mm04277571_s1 




α-SMA (Acta2) Mm00725412_s1 




Osteogenic Primers  
RUNx2 Mm00501584_m1 











Evaluating the Effects of Muscle Trauma on Heterotopic Ossification 
 Previous work in the lab showed that blunt force trauma can increase the 
bone volume induced by DBM implantation (W. T. Moore, 2019). However, it is 
unclear if muscle trauma can enhance ectopic bone formation using other ectopic 
bone formation models. Therefore, ectopic bone was induced using a different 
model, implantation of a gelatin sponge loaded with 0.3 μg of BMP-2. Animals 
received muscle trauma and were compared to control animals which did not 
receive the muscle trauma. Tissue was harvested at POD 2, 8, and 16. Plain film 
radiographs were collected to visualize the ectopic bone (Figure 2). Ectopic bone 
was not detected at POD 2 and 8; however mineralized ectopic bone tissue was 
detected at POD 16. It should be noted that there appeared to be a batch effect 
due to BMP-2. The first cohort of animals (n=16) enrolled for the study received 
previously reconstituted BMP-2 solution, while the remaining animals (n=29) 
received newly reconstituted BMP-2 solution. The radiographs clearly suggest 
varying amounts of mineralized ectopic bone tissue between batch 1 and batch 2 
of BMP-2. Batch 1 was used to collect BV measurements, while batch 2 was 





Figure 2: Plain Film Radiographs Demonstrating the Effects of Time and BMP-2 Batch 
Effect on Ectopic Bone Formation. Above are plain film radiographs of the femur and 
mineralized ectopic bone tissue of both injured and non-injured mice. A) Samples harvested at 
POD 2 and POD 8. Both time points show a lack of mineralized ectopic bone tissue. B) Samples 
harvested at POD 16 contain the first batch and second batch of BMP-2. White arrows indicate 
































Micro-computed tomography was then used to quantify the ectopic bone 
volume (BV), tissue volume (TV), trabecular number (TbN), trabecular thickness 
(TbTh), and trabecular spacing (TbSp) at POD 16 (Figures 3 and 4). Control mice 
showed 3.13 mm3 of BV, a TV of 73.34 mm3, a TbN of 2.52/mm, a TbTh of 0.14 
mm, and a TbSp of 1.44 mm. In comparison, injured mice resulted in 3.19 mm3 of 
BV, a TV of 69.08, a TbN of 2.23/mm, a TbTh of 0.15 mm, and a TbSp of 1.37 mm. 
No significance was detected between the control and injured mice. 
Since the radiographs indicated a possible BMP-2 batch effect, analysis 
was also performed with batch as a variable. Batch 1 resulted in a BV of 3.39 
mm3, TV of 100.52 mm3, TbN of 0.84/mm, TbTH of 0.14 mm, and TbSp of 1.87 
mm. Compared to Batch 2, which resulted in a BV of 2.71 mm3, TV of 12.58 
mm3, TbN of 5.45/mm, TbTh of 0.16 mm, and TbSp of 0.45 mm. Comparison of 
differences between batches of BMP-2 showed a significance in BV (p < 0.05), 
TV (p < 0.01), TbN (p < 0.01), TbTh (p < 0.05), and TbSp (p < 0.01).  
Three-dimensional (3D) renderings of the femur and ectopic bone were 
created to demonstrate the position of ectopic bone along the periosteal surface 
of the femur (Figure 5). The samples from the first batch demonstrated ectopic 
osteogenesis at the cortical bone/implant interface and along the periphery of the 
implant. Conversely, the samples that received the second batch of BMP-2 had 
ectopic bone localized along the length of the cortical bone extending beyond the 
limits of batch 1. This can be seen on 3D renderings and individual slices of the 
µCT scan (Figure 6). This indicates that there was a batch effect due to the BMP-
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2; however, the batch effect was restricted to a limited number of POD 16 and 













































































































Figure 3: Effect of Injury on Ectopic Bone. Samples were implanted with a gelatin 
sponge containing 0.3 µg of BMP-2 with or without injury and harvested on POD 16. 
Samples here are not separated by batch. Sample size for each group is n=12. A-E) 
Scatter plots comparing bone volume, tissue volume, trabecular number, trabecular 






Figure 4: Effect of BMP-2 Batch on Ectopic Bone. Samples were implanted with a 
gelatin sponge containing 0.3 µg of BMP-2 and harvested on POD 16. Samples from 
Batch 1 receive BMP-2 from the first batch and Batch 2 received BMP-2 from a second 
batch. Samples sizes were as follows: Batch 1 n=16 and Batch 2 n=8. A-E) Scatter plots 
comparing bone volume, tissue volume, trabecular number, trabecular thickness and 
trabecular spacing, respectively, between BMP-2 batch groups. * represented a 
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Figure 5: 3D Renderings Demonstrating Effect of BMP-2 Batch on Tissue Mineralization. 
Above are 3-demonstional renderings of periosteal ectopic bone along the femur. Note the 
proximal and distal ends of the femurs were not imaged as the ectopic bone did not extend 
beyond what is shown in the image. All the above samples were implanted with 0.3 µg of BMP-2 
loaded into Surgifoam® Absorbable Gelatin Sponge with or without injury and harvested at POD 
16. Purple represents ectopic bone. Left panel presents samples which did not receive muscle 
trauma, while the right panel shows samples in which trauma was induced following implantation. 
The top panel shows samples which received BMP-2 from the initial batch, and the bottom panel 




Comparing Gene Expression within the Implant During Ectopic Ossification 
 In determining the effect of muscle trauma on ectopic ossification, 
quantitative polymerase chain reaction (qPCR) was used to measure the gene 
expression within the developing ectopic bone tissue from both control and 
injured mice at POD 2, 8, and 16. All samples used were from the second batch 
of BMP-2. The relative expression of genes specific to endochondral ossification 
was quantified. Expression fold change was calculated relative to naïve mice, 
which did not undergo implantation surgery or injury, and was normalized to the 
18s ribosomal RNA housekeeping gene. 
 
Stem Cell Marker Expression 
 Paired related homeobox 1 (Prx1), sex determining region Y (SRY)-box 2 
(Sox2), paired box 7 (Pax7), and alpha-smooth muscle actin (α-SMA) are stem 
cell markers that appear early during development of the musculoskeletal 
Figure 6: Position of Ectopic Bone Along the Femur. Above 
are cuts from the middle of the stack of µCT images taken of the 
femur and ectopic bone. The right panel contains a cut from a 
from batch 1 of BMP-2, while the left panel contains a cut from a 
sample that that received the BMP-2 from the second batch. 
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system. Prx1 is an early marker of skeletogenesis appearing during embryonic 
development at the limb buds and is required for endochondral ossification 
(Kawanami et al., 2009; E. R. Moore et al., 2019). Sox2 is also expressed early 
in embryonic development. It is responsible for the maintenance, pluripotency, 
and self-renew of embryonic stem cells. It is also expressed in adult stem cells 
and maintains these populations (Feng & Wen, 2015) while also being 
upregulated during fracture repair (Bais et al., 2009). Pax7 has been well 
established to be a marker for satellite cells, a skeletal muscle stem cell, and 
previous research has shown that these cells can transdifferentiate into a 
chondrogenic lineage and participate in endochondral ossification (Abou‐Khalil et 
al., 2015). Lastly, α-SMA is predominantly known as a marker for perivascular 
stem cell populations, but has also been shown to be expressed by satellite cells, 
which demonstrate regenerative capabilities during angiogenesis; however, more 
recent research has shown that this population of cells can transdifferentiate into 
osteogenic cells (Matthews et al., 2016; Wanjare et al., 2013).  
 Prx1, Pax7, Sox2, and α-SMA expression were observed at POD 2, 8, and 
16 in both control and injured animals. Prx1 expression significantly increased at 
POD 8 (p < 0.01) and 16 (p < 0.05) compared to POD 2 for both control and 
injured groups. No significant difference was observed between POD 8 and 16. 
Pax7 did not show significant temporal changes; however, there was an 
increased expression compared to naïve femur tissue.  Conversely, Sox2 
expression peaked early at POD 2 compared to POD 8 (p < 0.05) and 16 (p < 
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0.01). Lastly, α-SMA showed significantly higher expression peaking at POD 8 
compared to both POD 2 (p < 0.01) and POD 16 (p < 0.01). A significant 
difference was also seen between POD 2 and POD 16 (p < 0.05) (Figure 7). No 
significant differences were observed between sex or injury groups. 
 
Chondrogenesis Marker Expression 
 Sox9, Acan, and Col10a1 were used to detect chondrogenesis. 
Expression of chondrogenic markers was observed at POD 8 and 16. Sox9 and 
Acan expression peaked in both control and injury groups at POD 8, while 
Col10a1 expression was highest at POD 16 in both control and injured samples. 




Figure 7: Comparison of Stem Cell Markers in Ectopic Bone Over Time. Above are scatter 
plots comparing the expression Prx1, Pax7, Sox2 and α-SMA at POD 2, 8, and 16. Samples 
sizes are as follows: POD 2 No Injury n = 5, POD 2 Injury n=4, POD 8 No Injury n = 5, POD 8 
Injury n = 6, POD 16 No Injury n = 7, and POD 16 Injury n = 6. Significance is represented with 
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Figure 8: Comparison of Chondrogenic Markers in Ectopic Bone Over Time. Above are 
scatter plots comparing the expression Sox9, Acan and Col10a1 at POD 2, 8, and 16. Samples 
sizes are as follows: POD 2 No Injury n = 5 (Sox9 and Acan n = 4), POD 2 Injury n=4 (Sox9 
and Acan n = 3), POD 8 No Injury n = 5, POD 8 Injury n = 6, POD 16 No Injury n = 7, and POD 
16 Injury n = 6. Of note Sox9 and Acan both had Significance is represented with * for a p < 
0.5, and ** for a p < 0.01. 
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Osteogenesis Marker Expression 
 Osteogenic gene expression was measured using RUNX2, Sp7, and 
DMP-1. For each osteogenic gene, expression peaked at POD 16. Significance 
was seen in the expression of RUNX2 between POD 16 and both POD 2 (p < 
0.01) and POD 8 (p < 0.05). Significance for Sp7 was only observed between 
POD 16 and 2 (p < 0.05), while significance with DMP-1 expression was only 
observed between POD 16 and 8 (p < 0.05) (Figure 9). 
  
BMP Signaling Expression 
 Expression of genes involved in the BMP signaling cascade was 
measured using the markers BMP-2, BMP-7, Id-1, and myostatin (MSTN). 
Animals harvested at POD 16 expressed the highest amount of BMP-2 and 
BMP-7. A significant difference with BMP-2 expression was observed between 
POD 2 and 16 (p < 0.01). Additionally, BMP-7 expression was significantly 
different between POD 16 and both POD 2 and 8 at a significance of p < 0.05. Id-
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Figure 9: Comparison of Osteogenic Markers in Ectopic Bone Over Time. Above are 
scatter plots comparing the expression RUNX2, Sp7 and DMP-1 at POD 2, 8, and 16. Samples 
sizes are as follows: POD 2 No Injury n = 5 (DMP-1 n = 3), POD 2 Injury n=4 (DMP-1 n = 2), 
POD 8 No Injury n = 5, POD 8 Injury n = 6, POD 16 No Injury n = 7, and POD 16 Injury n = 6. 



































No Injury Injury Average






























No Injury Injury Average




























No Injury Injury Average





























No Injury Injury Average




Figure 10: Comparison of BMP Signaling Markers in Ectopic Bone Over Time. Above are 
scatter plots comparing the expression BMP-2, BMP-7, Id-1 and MSTN at POD 2, 8, and 16. 
Samples sizes are as follows: POD 2 No Injury n = 5 (MSTN n = 3), POD 2 Injury n=4 (MSTN 
n = 3), POD 8 No Injury n = 5, POD 8 Injury n = 6, POD 16 No Injury n = 7, and POD 16 Injury 




Effect of BMP-2 Batch on Ectopic Bone 
Periosteal gelatin sponge implants loaded with BMP-2 induced 
endochondral heterotopic ossification in both injured and control mice. However, 
a batch effect was observed in our study, which interestingly resulted in the 
formation of ectopic bone of similar volume but differed in tissue volume and 
trabecular morphology. Bone tissue was distributed unevenly, with the first batch 
samples showing tissue at the cortical bone/implant interface and along the 
periphery of the implant. In contrast, the second batch was localized along the 
periosteal surface. These differences were observed on plain film radiographs, 
and 3D renderings of the samples of samples harvest POD 16 (Figures 4, 5, and 
6). These findings suggest that there was a change between the batches of 
BMP-2 used in this study, likely a result of human error in handling or 
preparation.  
 
Effects of Muscle Trauma Ectopic Bone Development 
 A comparison of ectopic bone volumes (BV), tissue volumes (TV), 
trabecular number (TbN), trabecular thickness (TbTh), and trabecular spacing 
(TbSp) showed no significant differences between injury cohorts. These findings 
are not consistent with published literature (Li et al., 2019) or previous findings in 
the lab, which showed muscle injury does enhance ectopic bone formation 
resulting in increased bone volume (W. T. Moore, 2019). An explanation of this 
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inconsistent observation could be that the dose of BMP-2 used in the study was 
enough to stimulate ectopic bone formation in both sample groups regardless of 
whether an injury or no injury was induced. Furthermore, a previous study 
showed that that gelatin sponge as opposed to a collagen gel and fibrin sealant 
produced hypertrophic bone, whereas the other models formed bone resemblant 
of the surrounding bone (Usas et al., 2009).  This could offer another explanation 
on why this study showed nearly twice as much bone volume in both control and 
injured samples compared to samples in previous work in the lab (W. T. Moore, 
2019). Future experiments using a 0.1 µg of BMP-2 could be performed to see if 
a lower dose of BMP-2 results in a difference between control and injured 
animals. 
 
Variations in Gene Expression in Heterotopic Ossification Over Time 
 This study suggests that varying stem cell populations contribute to 
ectopic bone formation; however, the temporal progression may be unique to the 
differing stem cell populations. Sox2 was the only gene investigated that showed 
peak expression as POD 2, suggesting an early presence of adult stem cells in 
the implant. The stark drop in expression of Sox2 at POD 8 and 16 suggests the 
loss of pluripotency and progression of cell differentiation (Zhang & Cui, 2014). 
Both Prx1 and α-SMA showed increased expression at POD 8 and was 
maintained through POD16. It was not surprising that both populations of cells 
contribute to postnatal bone formation based on previous studies (Bennie, 2017; 
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Matthews et al., 2016). However, the later peak and maintenance was interesting 
and may suggest that these cell populations expand during endochondral 
ossification or that these transcription factors are regulating cell differentiation 
and function, as suggested by  Esposito et al. (2020). Although Pax7 expression 
did not change across time, there was increased expression compared to the 
naïve femur tissue. Since Pax7 is a muscle satellite stem cell marker, this 
indicates that there may be a recruitment of cells from the surrounding muscle.  
 
 In general, the expression of chondrogenic and osteogenic genes is 
consistent with the stages of endochondral ossification. Early chondrogenic 
genes, Sox9 and Acan, peak expression at POD 8, while late-stage 
chondrogenic gene Col10a1 and osteogenic genes peaked at POD 16. These 
results are consistent with previous findings that demonstrated peak 
chondrogenic gene expression at POD 8, while osteoblast-specific genes peaked 
later at POD 16 animals (B. Bragdon et al., 2017). Conversely, this study did 
show Col10a1 peaking at POD 16, which suggests that there may be a delay in 
osteogenesis. Similar to the osteogenic gene expression BMP-2 and BMP-7 
signaling was expressed at higher POD 16 compared to POD 2 and 8. However, 
expression of Id-1 was comparable at all time points, despite this gene being 
downstream of BMP-2 and BMP-7 in the BMP signaling cascade. This 
observation could be explained by the supplementation of BMP-2 during surgical 
implantation. As observed in previous research (Katagiri et al., 2002), BMP-2 
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stimulates the expression of Id-1, which would explain the early expression of Id-
1. Similarly, MSTN expression was constant at all three time points, consistent 
with data from previous research in the lab (Murphy, 2020). 
 
Conclusion and Limitations 
The impact of muscle injury on the development of ectopic bone is difficult 
to assess with this study's results. However, significant gene expression changes 
were observed that reaffirmed previous findings regarding the specific pattern 
correlating with the progression through endochondral ossification, particularly 
chondrogenesis peaking at POD 8 and osteogenesis present in POD 16 animals. 
However, small differences between injury groups are hard to distinguish due to 
the small sample size in each cohort and high variance within groups. Further 
studies on the expression of endochondral ossification genes in developing 
ectopic bone would further our general understanding and lead to more 
significant findings within groups. Furthermore, this study did suggest the 
possibility of some delay in osteogenesis in the POD 16 samples, which could 
indicate the need to study the gene expression of implants at later time points, 
like POD 21 or 31. 
Micro-computed tomography data identified a batch effect within the study. The 
appearance of a batch effect introduced a new confounding variable with stark 
differences between both batches. These differences limited the ability to 
compare injured and uninjured samples in the µCT analysis of the ectopic bone 
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due to the small sample size for batch 2. Though some trend was noticeable 
when removing the initial batch samples from the analysis, this population was 
too small to provide any significant comparison. Further studies using the same 
animal model would increase sampling and provide a better representation of the 
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